SOFIVA GENOMICS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.1 TWD | +3.97% |
|
+20.32% | +66.10% |
| 04/06 | Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 26, 2024 | CI |
| 15/05 | Sofiva Genomics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 496M 15.29M 1.28B | Sales 2023 | 467M 14.39M 1.2B | Capitalization | 876M 27.01M 2.26B |
|---|---|---|---|---|---|
| Net income 2022 | 42M 1.3M 108M | Net income 2023 | 11M 339K 28.32M | EV / Sales 2022 | 1.39 x |
| Net cash position 2022 | 96.29M 2.97M 248M | Net cash position 2023 | 76.45M 2.36M 197M | EV / Sales 2023 | 1.71 x |
| P/E ratio 2022 |
18.4
x | P/E ratio 2023 |
76
x | Employees | - |
| Yield 2022 |
2.72% | Yield 2023 |
0.49% | Free-Float | 52.14% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.97% | ||
| 1 week | +20.32% | ||
| Current month | +20.32% | ||
| 1 month | +48.20% | ||
| 3 months | +63.31% | ||
| 6 months | +73.72% | ||
| Current year | +66.10% |
1 week
54.70
69.90
1 month
42.1569.90
Current year
39.5069.90
1 year
37.3069.90
3 years
36.0569.90
5 years
36.05102.00
10 years
36.05155.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Cheng Hung
CEO | Chief Executive Officer | - | 15/12/15 |
I Ning Su
CEO | Chief Executive Officer | - | 15/12/15 |
Fu Chien Chang
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Po Cheng Ko
BRD | Director/Board Member | - | 15/17/15 |
Fan Chuan Shih
BRD | Director/Board Member | - | 15/17/15 |
I Ning Su
CEO | Chief Executive Officer | - | 15/12/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 68.1 | +3.97% | 591,710 |
| 06/24/06 | 65.5 | +6.16% | 1,048,238 |
| 05/24/05 | 61.7 | +9.98% | 543,540 |
| 04/24/04 | 56.1 | -9.81% | 867,653 |
| 03/24/03 | 62.2 | +9.89% | 1,136,449 |
End-of-day quote Taipei Exchange, June 07, 2024
More quotes
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.
| 1st Jan change | Capi. | |
|---|---|---|
| +66.10% | 44.85M | |
| -41.97% | 7.92B | |
| +5.99% | 3.51B | |
| -4.31% | 2.18B | |
| -21.69% | 1.97B | |
| -24.94% | 1.58B | |
| +31.45% | 1.14B | |
| +26.75% | 792M | |
| -9.83% | 690M | |
| -26.33% | 532M |
- Stock Market
- Equities
- 6615 Stock
